Compare · GILD vs VCEL
GILD vs VCEL
Side-by-side comparison of Gilead Sciences Inc. (GILD) and Vericel Corporation (VCEL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both GILD and VCEL operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- GILD is the larger of the two at $184.47B, about 83.4x VCEL ($2.21B).
- GILD has been more active in the news (12 items in the past 4 weeks vs 2 for VCEL).
- GILD has more recent analyst coverage (25 ratings vs 11 for VCEL).
- Company
- Gilead Sciences Inc.
- Vericel Corporation
- Price
- -
- -
- Market cap
- $184.47B
- $2.21B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 1992
- News (4w)
- 12
- 2
- Recent ratings
- 25
- 11
Gilead Sciences Inc.
Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of human immunodeficiency virus (HIV) infection; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr; Tizona; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos; Janssen; Japan Tobacco, Inc.; Gadeta; Bristol-Myers Squibb Company; Merck; and Novo Nordisk A/S. The company was founded in 1987 and is headquartered in Foster City, California.
Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, and distributes cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product includes, NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
Latest GILD
- European Commission Expands Role of Gilead’s Trodelvy® in First-Line Metastatic Triple-Negative Breast Cancer Across PD-L1 Status
- Director Bluestone Jeffrey exercised 5,000 shares at a strike of $67.04 and sold $725,078 worth of shares (5,000 units at $145.02) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Financial Officer Dickinson Andrew D sold $415,080 worth of shares (3,000 units at $138.36) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 165,646 units (SEC Form 4)
- Chief Comm & Corp Aff Officer Mercier Johanna exercised 25,000 shares at a strike of $67.07 and sold $3,853,908 worth of shares (28,000 units at $137.64) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 118,234 units (SEC Form 4)
- EVP Gen Counsel, Legal & Comp Cain Wettan Keeley M covered exercise/tax liability with 2,908 shares and converted options into 6,002 shares, increasing direct ownership by 58% to 8,454 units (SEC Form 4)
- SEC Form S-3ASR filed by Gilead Sciences Inc.
- SEC Form 10-Q filed by Gilead Sciences Inc.
- CORRECTING and REPLACING Gilead Sciences Announces Second Quarter 2026 Financial Results
- Chairman & CEO O'Day Daniel Patrick sold $1,954,694 worth of shares (15,000 units at $130.31) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 592,133 units (SEC Form 4)
- Gilead Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest VCEL
- Cosmetic Surgery's Next Debate: Rebuild Tissue, Not Fill It
- Chief Operating Officer Halpin Michael exercised 10,000 shares at a strike of $16.66 and sold $468,400 worth of shares (10,000 units at $46.84) as part of a pre-agreed trading plan (SEC Form 4)
- Principal Accounting Officer Siegal Jonathan exercised 4,500 shares at a strike of $31.51 and sold $220,050 worth of shares (4,500 units at $48.90) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 10-Q filed by Vericel Corporation
- Vericel Corporation filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Vericel Reports Second Quarter 2026 Financial Results, Raises Full-Year Financial Guidance and Announces Share Repurchase Program
- Vericel to Report Second Quarter 2026 Financial Results on July 30, 2026
- Principal Accounting Officer Siegal Jonathan exercised 2,500 shares at a strike of $29.82 and sold $122,667 worth of shares (2,732 units at $44.90) as part of a pre-agreed trading plan, decreasing direct ownership by 21% to 886 units (SEC Form 4)
- Chief Financial Officer Mara Joseph Anthony Jr sold $223,750 worth of shares (5,000 units at $44.75) as part of a pre-agreed trading plan, decreasing direct ownership by 24% to 16,009 units (SEC Form 4)
- Chief Medical Officer Hopper Jonathan Mark sold $450,000 worth of shares (10,000 units at $45.00) as part of a pre-agreed trading plan and exercised 10,000 shares at a strike of $29.82 (SEC Form 4)